Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. (noting the metadata reference to Avalo Therapeutics appears to be a discrepancy, as the filing text explicitly identifies the registrant as Cerecor Inc.) on November 4, 2019, reporting events occurring on November 1, 2019. The filing details the closing of a material asset disposition and the execution of related definitive agreements.
Key Financial Metrics and Transaction Details
- Transaction Proceeds: The Company received net proceeds of approximately $17 million in a combination of cash and convertible preferred stock from Aytu Bioscience, Inc.
- Liabilities Assumed: Aytu assumed approximately $26 million of the Company's liabilities, including $15 million payable to Deerfield CSF, LLC and other liabilities exceeding $11 million.
- Assets Sold: The pediatric portfolio including Aciphex Sprinkle, Cefaclor for Oral Suspension, Karbinal ER, Flexichamber, Poly-Vi-Flor, and Tri-Vi-Flor.
- Ownership Structure: Armistice Capital Master Fund, Ltd., the Company's largest shareholder, beneficially owned approximately 63% of the Company's common stock as of November 1, 2019.
Material Changes and Agreements
The primary material change is the completion of the sale of the pediatric portfolio to Aytu Bioscience, Inc. Concurrently, the Company entered into three key agreements:
- First Amendment to Asset Purchase Agreement: Made technical changes to the original October 10, 2019 agreement, specifically regarding the mechanics of converting Aytu's convertible preferred stock received by Cerecor.
- Guarantee: Cerecor guaranteed Aytu's payment of the assumed liabilities (approximately $26 million) to the Creditors (Deerfield CSF, LLC, Peter Steelman, and James Flynn).
- Contribution Agreement: Established contribution rights and obligations between Cerecor, Armistice, and Avadel US Holdings Inc. regarding payments made to Creditors under their respective guarantees. This related-party transaction was approved by the Audit Committee.
Outlook, Risks, and Management Commentary
The filing confirms the transaction was reviewed and approved by a special committee of independent directors due to the related-party nature of the deal (shared ownership with Armistice and shared board members). The Company issued a press release on November 4, 2019, announcing the closing. No specific forward-looking guidance or financial outlook for future periods is provided in this specific filing; the focus is strictly on the completion of the asset disposition and the restructuring of associated liabilities.
Investor Verification Checklist
- Verify the exact split of the $17 million net proceeds between cash and convertible preferred stock.
- Confirm the specific terms and conversion mechanics of the Aytu convertible preferred stock received.
- Review the full text of the Guarantee to understand the extent of Cerecor's liability exposure if Aytu defaults on the $26 million obligation.
- Assess the impact of the Contribution Agreement on Cerecor's future cash flow obligations to Creditors.
- Confirm the updated capitalization table following the issuance of new shares or stock to Aytu.